Tryptamine Therapeutics Ltd (ASX:TYP) is aiming to raise $6 million through a Placement to support acceleration of a clinical trial strategy for the company’s IV-infused psilocybin treatment, or TRP-8803. The company has received commitments from new and current investors – these including sophisticated and institutional investors – wanting to take part in the Placement, which will involve the issue of 300 million new fully paid shares priced at 2 cents each. The funds from the capital raising will be plugged into pushing ahead with a trial strategy for TRP-8803, which has been shown to have i…
